Construction of Bifidobacterium Infantis/CD targeting gene therapy system

Chinese-German Journal of Clinical Oncology

Volumn 4, Issue 4, 2005, Pages 244-247

  Yi, Cheng ^a   Huang, Ying ^b   Guo, Zhiying ^b   Wang, Shuren ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Bifidobacterium infantis; Cytosine deaminase; Gene therapy

Indexed keywords

EID: 24944484720     PISSN: 16101979     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10330-004-0339-4     Document Type: Article

References (17)

1. Miller CR, Gustin AN, Buchsbaum DJ, et al. Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: A sensitive method for assessing 5-fluorocytosine toxicity in vitro. Anal Biochem, 2002, 301: 189-199.
2. Miyagi T, Koshida K, Hori O, et al. Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system. J Gene Med, 2003, 5: 30-37.
3. Plumb JA, Bilsland A, Kakani R, et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the prodrug CB1954. Oncogene, 2001, 20: 7797-7803.
4. Brown NL, Lemoine NR. Clinical trials with GDEPT: Cytosine deaminase and 5-fluorocytosine. Methods Mol Med, 2004, 90: 451-457.
5. Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res, 2001, 7: 3314-3324.
6. Denny WA. Prodrug strategies in cancer therapy. Eur J Med Chem, 2001, 36: 577-595.
7. Liu SC, Minton NP, Giaccia AJ, et al. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther, 2002, 9: 291-296.
8. Nuyts S, Van Mellaert L, Theys J, et al. Clostridium spores for tumor-specific drug delivery. Anticancer Drugs, 2002, 13: 115-125.
9. Yazawa K, Fujimori M, Amano J, et al. Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors. Cancer Gene Ther, 2000, 7: 269-274.
10. Wu Y, Yi C, Wang S, et al. Investigation on tumor-targeting characteristics of Bifidobacterium infantis toward melanoma in mice. J Sichuan Univ (Med Sci Edi), 2003, 34: 435-438.
11. Vaupel PW. Oxygenation of solid tumors in drug resistance in oncology. In: Teicher BA, ed. New York: Marcel Dekker, 1993. 53-85.
12. Nagy H, Panis Y, Fabre M, et al. Are hepatomas a good target for suicide gene therapy? An experimental study in rats using retroviral-mediated transfer of thymidine kinase gene. Surgery, 1998, 123: 19-24.
13. Fujimori M, Amano J, Taniguchi S. The genus Bifidobacterium for cancer gene therapy. Curr Opin Drug Discov Devel, 2002, 5: 200-203.
14. Yazawa K, Fujimori M, Nakamura T, et al. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat, 2001, 66: 165-170.
15. Nakamura T, Sasaki T, Fujimori M, et al. Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. Biosci Biotechnol Biochem, 2002, 66: 2362-2366.
16. Kim TB, Song SH, Kang SC, et al. Quantitative comparison of lactose and glucose utilization in Bifidobacterium longum cultures. Biotechnol Prog, 2003, 19: 672-675.
17. Makelainen H, Tahvonen R, Salminen S, et al. In vivo safety assessment of two Bifidobacterium longum strains. Microbiol Immunol, 2003, 47: 911-914.